CoChat

Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function

Open access
Duman, Ronald S., Shinohara, Ryota, Fogaça, Manoela V., Hare, Brendan · 2019 · Molecular Psychiatry
Cited by 154

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Abstract

Efforts to develop efficacious antidepressant agents with novel mechanisms have been largely unsuccessful since the 1950’s until the discovery of ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist that produces rapid and sustained antidepressant actions even in treatment-resistant patients. This finding has ushered in a new era for the development of novel rapid-acting antidepressants that act at the NMDA receptor complex, but without dissociative and psychotomimetic side effects of ketamine. Here, we review the current state of rapid-acting antidepressant drug development, including NMDA channel blockers, glycine site agents, and allosteric modulators, as well as ketamine stereoisomers and metabolites. In addition, we focus on the neurobiological mechanisms underlying the actions of these diverse agents and discuss evidence of convergent mechanisms including increased brain-derived neurotrophic factor signaling, increased synthesis of synaptic proteins, and most notably increased GluR1 and synaptic connectivity in the medial prefrontal cortex. These convergent mechanisms provide insight for potential additional novel targets for drug development (e.g., agents that increase synaptic protein synthesis and plasticity). Importantly, the convergent effects on synapse formation and plasticity also reverse the well-documented neuronal and synaptic deficits associated with stress and depression, and thereby target the underlying pathophysiology of major depressive disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-019-0400-x

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 90 references

Research works printed but not linked: 63

  1. Curtin SC, Warner M, Hedegaard H. Increase in suicide in the United States, 1999–2014. NCHS Data Brief. 2016;241:1–8.
  2. Sinner B, Graf BM. Modern Anesthetics. In: Schüttler J, Schwilden H, (eds). Handbook of Experimental Pharmacology. 182. Berlin, Heidelberg: Springer; 2008. p. 313–33.
  3. Henter ID, de Sousa RT, Zarate CA, Jr. Glutamatergic Modulators in Depression. Harv Rev Psychiatry. 2018;26:307–19. · DOI · Paper page
  4. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73:1133–41. · DOI · Paper page
  5. Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K. (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psych. 2017;85:e43–e44. · DOI · Paper page
  6. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–39. · DOI · Paper page
  7. Nicoll RA, Malenka RC. Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature. 1995;377:115–8. · DOI · Paper page
  8. Ogden KK, Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci. 2011;32:726–33. · DOI · Paper page
  9. Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150:1081–105. · DOI · Paper page
  10. Mealing GA, Lanthorn TH, Murray CL, Small DL, Morley P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther. 1999;288:204–10.
  11. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 1997;77:309–23. · DOI · Paper page
  12. MacQueen G, Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry. 2011;16:252–64. · DOI · Paper page
  13. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69:754–61. · DOI · Paper page
  14. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33:67–75. · DOI · Paper page
  15. Pazini F, Cunha M, Rosa J, Colla A, Lieberknecht V, Oliveira A, et al. Creatine, similar to ketamine, counteracts depressive-like behavior induced by corticosterone via PI3K/Akt/mTOR pathway. Mol Neurobiol. 2016;53:6818–34. · DOI
  16. Harraz M, Tyagi R, Cortés P, Snyder S. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psych. 2016;21:313–9. · DOI · Paper page
  17. Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry. 2018;84:591–600. · DOI · Paper page
  18. Sutton MA, Taylor AM, Ito HT, Pham A, Schuman EM. Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron. 2007;55:648–61. · DOI · Paper page
  19. Hill JL, Martinowich K. Activity-dependent signaling: influence on plasticity in circuits controlling fear-related behavior. Curr Opin Neurobiol. 2016;36:59–65. · DOI
  20. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15):1768–77. · DOI · Paper page
  21. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260–5. · DOI · Paper page
  22. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314:140–3. · DOI · Paper page
  23. Lepack A, Fuchikami M, Dwyer J, Banasr M, Aghajanian G, Duman R. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18:1.
  24. Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482–92. · DOI · Paper page
  25. Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research. 2018; 7:659. · DOI · Paper page
  26. Fan LZ, Nehme R, Adam Y, Jung ES, Wu H, Eggan K, et al. All-optical synaptic electrophysiology probes mechanism of ketamine-induced disinhibition. Nat Methods. 2018;15:823–31. · DOI · Paper page
  27. Preskorn S, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-asparate antagonist, CP-101, 606, in patients with treatment-refractory major depressive dosorder. J Clin Psychopharmacol. 2008;28:631–7. · DOI · Paper page
  28. Park L, Furey M, Nugent AC, Farmer C, Ellis J, Szczepanik J, et al. Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder. Int J Neuropsychopharmacol. 2019;22:10–8. · DOI · Paper page
  29. Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74:742–9. · DOI · Paper page
  30. Yang C, Ren Q, Qu Y, Zhang J, Ma M, Dong C, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psych. 2018;83:1. · doi:10.1016/s0006-3223(18)31419-7
  31. Zhang K, Toki H, Fujita Y, Ma M, Chang L, Qu Y, et al. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Psychopharmacol (Berl). 2018;235:3177–85. · DOI
  32. Shirayama Y, Hashimoto K. Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness Model:comparison with (R)-ketamine. Int J Neuropsychopharmacol. 2018;21:84–8. · DOI · Paper page
  33. Clements JD, Westbrook GL. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron. 1991;7:605–13. · DOI · Paper page
  34. Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. J Pharmacol Exp Ther. 2015;355:76–85. · DOI
  35. Wallace M, White A, Grako KA, Lane R, Cato AJ, Snodgrass HR. Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. Scand J Pain. 2017;17:243–51. · DOI · Paper page
  36. Papp M, Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol. 1996;316:145–51. · DOI
  37. Malkesman O, Austin DR, Tragon T, Wang G, Rompala G, Hamidi AB, et al. Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol. 2012;15:1135–48. · DOI · Paper page
  38. Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74:734–41. · DOI
  39. Chen KT, Tsai MH, Wu CH, Jou MJ, Wei IH, Huang CC. AMPA receptor-mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: insertion of ampa receptor may play a role. Front Behav Neurosci. 2015;9:162.
  40. Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, et al. The development of rapastinel (Formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol. 2017;15:47–56. · DOI · Paper page
  41. Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21:140–9. · DOI · Paper page
  42. (Glyx-13), A rapid acting antidepressant, does not increase extracellular levels of dopamine and glutamate in rat medial prefrontal cortex. Proceedings of the American College of Neuropsychopharmacology, Hollywood, Florida, 2016.
  43. Hascup ER, Hascup KN, Stephens M, Pomerleau F, Huettl P, Gratton A, et al. Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J Neurochem. 2010;115:1608–20. · DOI · Paper page
  44. Xi ZX, Baker DA, Shen H, Carson DS, Kalivas PW. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J Pharmacol Exp Ther. 2002;300:162–71. · DOI · Paper page
  45. Koike H, Chaki S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res. 2014;271:111–5. · DOI
  46. Joffe ME, Conn PJ. Antidepressant potential of metabotropic glutamate receptor mGlu2 and mGlu3 negative allosteric modulators. Neuropsychopharmacology. 2018;44:214–36.
  47. Engers JL, Rodriguez AL, Konkol LC, Morrison RD, Thompson AD, Byers FW, et al. Discovery of a selective and CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 with antidepressant and anxiolytic activity in rodents. J Med Chem. 2015;58:7485–500. · DOI
  48. Fukumoto K, Iijima M, Funakoshi T, Chaki S. Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine. Int J Neuropsychopharmacol. 2018;21:371–81. · DOI · Paper page
  49. Bjorkholm C, Marcus MM, Konradsson-Geuken A, Jardemark K, Svensson TH. The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism. Eur Neuropsychopharmacol. 2017;27:411–7. · DOI
  50. Shinohara R, Taniguchi M, Ehrlich AT, Yokogawa K, Deguchi Y, Cherasse Y, et al. Dopamine D1 receptor subtype mediates acute stress-induced dendritic growth in excitatory neurons of the medial prefrontal cortex and contributes to suppression of stress susceptibility in mice. Mol Psychiatry. 2018;23:1717–30. · DOI
  51. D’Aquila PS, Collu M, Pani L, Gessa GL, Serra G. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur J Pharmacol. 1994;262:107–11. · DOI · Paper page
  52. Fukumoto K, Iijima M, Chaki S. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacol (Berl). 2014;231:2291–8. · DOI
  53. Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology. 1999;90:174–82. · DOI · Paper page
  54. Yoon G, Petrakis IL, Krystal JH. Preliminary evidence against a role for opiate receptor signaling in the antidepressant effects of R/S-ketamine. JAMA Psychiatry. 2018;554:317–22.
  55. Sanacora G. Caution against over-interpreting opiate receptor stimulation as mediating antidepressant effects of ketamine. Am J Psychiatry. 2018, in press. · DOI
  56. Northoff G, Sibille E. Cortical GABA neurons and self-focus in depression: a model linking cellular, biochemical and neural network findings. Mol Psychiatry. 2014;19:959. · DOI
  57. Lin LC, Sibille E. Transcriptome changes induced by chronic psychosocial/environmental or neuroendocrine stressors reveal a selective cellular vulnerability of cortical somatostatin (SST) neurons, compared with pyramidal (PYR) neurons. Mol Psychiatry. 2015;20:285. · doi:10.1038/mp.2015.24
  58. Czéh B, Vardya I, Varga Z, Febbraro F, Csabai D, Martis L-S, et al. Long-term stress disrupts the structural and functional integrity of GABAergic neuronal networks in the medial prefrontal cortex of rats. Front Cell Neurosci. 2018;12:148. · DOI · Paper page
  59. Piantadosi SC, French BJ, Poe MM, Timic T, Markovic BD, Pabba M, et al. Sex-dependent anti-stress effect of an alpha5 subunit containing GABAA receptor positive allosteric modulator. Front Pharmacol. 2016;7:446. · DOI · Paper page
  60. Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectr. 2015;20:48–59. · DOI · Paper page
  61. MacKenzie G, Maguire J. Neurosteroids and GABAergic signaling in health and disease. Biomol Concepts. 2013;4:29–42. · DOI · Paper page
  62. Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37:109–22. · DOI · Paper page
  63. De Simoni S, Schwarz AJ, O’Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage. 2013;64:75–90. · DOI

Cited by

See all 154

Metadata

Authors
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B.
Venue
Molecular Psychiatry
Published
2019-03-20
Volume
24
Issue
12
Pages
1816-1832
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2923276583
Cited by
154
References
90
FWCI
11.36
Type
journal article
Language
en
Open access
green
Licence
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH045481, MH093897)
  • State of Connecticut Department of Mental Health and Addiction Services

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. https://app.cochat.ai/papers/10.1038/s41380-019-0400-x
The paper
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019). Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0400-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.